The aim of the study is to substantiate the treatment tactics for patients with neuroendocrine tumors (NET), which allows to improve the outcomes of the disease and the quality of life of patients. Materials and methods. We have studied the results of treatment of 235 patients with NET localized in the pancreas (42.1% of the patients), in the gastrointestinal tract (54.1%); localization of the primary tumor was not found in 3.8%. Localized oncological process was diagnosed in 52.8% of patients, locally-common - in 15.7%, generalized - in 31.5%. Results. Surgical treatment was performed for 82.6% of patients. The criteria for selecting the volume of surgery in patients with NET were as follows: 1) the localization of the tumor; 2) the size; 3) the degree of malignancy; 4) the depth of invasion of the organ wall (for GI tract) 4) communication with the main pancreatic duct and main vessels (for pancreas). It has been established that complex treatment compared to drug therapy provided a two-fold increase in survival of patients of NET (G1-G2) (from 29.9 months up to 60 months), for neuroendocrine carcinoma (NEC) G3 an increase was 2.9 times (from 10.1 months) up to 28.5 months.). Adverse prognostic criteria for the course of the disease have been determined: 1) localization of the tumor in the pancreas; 2) metastatic lesion of the liver type 3; 3) the presence of NEC; 4) carrying out drug therapy as the only type of treatment. Conclusion. The surgical method is the main one in the treatment of NET at all stages of the disease. In patients with generalized NET, preference should be given to comprehensive treatment.